[{"AccountsPayableCurrent_0_Q1_USD":10260000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":-21362000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q1_USD":-25000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":457000.0,"DefinedContributionPlanEmployerMatchingContributionPercent_1_Q1_pure":0.0,"AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1_Q1_USD":2211000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q1_USD":25000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":185774000.0,"OtherAssetsCurrent_0_Q1_USD":4062000.0,"IncreaseDecreaseInOtherCurrentAssets_1_Q1_USD":-759000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1_Q1_USD":16.94,"ProceedsFromStockOptionsExercised_1_Q1_USD":370000.0,"DepreciationDepletionAndAmortization_1_Q1_USD":86000.0,"DeferredIncomeTaxExpenseBenefit_1_Q1_USD":0.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-26154000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":401000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0_Q1_USD":63082000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1_Q1_shares":717000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0_Q1_USD":5.65,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0_Q1_shares":2626106.0,"DividendsCommonStock_1_Q1_USD":0.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0_Q1_USD":53554000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1_Q1_USD":50000.0,"FairValueAssetsLevel2ToLevel1TransfersAmount_0_Q1_USD":0.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1_Q1_USD":25000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q1_pure":0.11,"OperatingLeaseRightOfUseAsset_0_Q1_USD":1865000.0,"OperatingLeasePayments_1_Q1_USD":188000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":1543000.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":548000.0,"OperatingLeaseLiability_0_Q1_USD":2091000.0,"OperatingLeaseCost_1_Q1_USD":174000.0,"NumberOfOperatingSegments_1_Q1_segment":1.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q1_USD":477000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q1_USD":563000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q1_USD":754000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q1_USD":647000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q1_USD":540000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0_Q1_USD":64000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q1_USD":2568000.0,"IncreaseDecreaseInOtherNoncurrentAssets_1_Q1_USD":11000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_1_Q1_USD":0.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_1_Q1_USD":0.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q1_USD":0.0,"OtherAssetsNoncurrent_0_Q1_USD":381000.0,"CurrentIncomeTaxExpenseBenefit_1_Q1_USD":0.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1_Q1_USD":29.26,"NetIncomeLoss_1_Q1_USD":-26179000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-21756000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":-26000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":370000.0,"LiabilitiesCurrent_0_Q1_USD":14843000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":194074000.0,"Liabilities_0_Q1_USD":18744000.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":1740000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-26179000.0,"GeneralAndAdministrativeExpense_1_Q1_USD":8125000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.66,"CommonStockValue_0_Q1_USD":4000.0,"CommonStockSharesIssued_0_Q1_shares":39757623.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":185774000.0,"AssetsCurrent_0_Q1_USD":189836000.0,"Assets_0_Q1_USD":194074000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":4721824.0,"AdditionalPaidInCapital_0_Q1_USD":367293000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":75000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":26000.0,"ProfitLoss_1_Q1_USD":-26179000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":1992000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-192042000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1_Q1_USD":14.35,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0_Q1_USD":13.49,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q1_shares":4697095.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":568000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q1_USD":370000.0,"StockIssuedDuringPeriodSharesStockOptionsExercised_1_Q1_shares":25778.0,"ShareBasedCompensation_1_Q1_USD":2211000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":18622000.0,"PreferredStockValue_0_Q1_USD":null,"ResidualValueOfLeasedAsset_0_Q1_USD":0.0,"PreferredStockSharesIssued_0_Q1_shares":0.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.0001,"OperatingIncomeLoss_1_Q1_USD":-26747000.0,"OperatingExpenses_1_Q1_USD":26747000.0,"CommonStockSharesAuthorized_0_Q1_shares":100000000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.0001,"CommitmentsAndContingencies_0_Q1_USD":null,"AccruedLiabilitiesCurrent_0_Q1_USD":4035000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":39753583.0,"StockholdersEquity_0_Q1_USD":175330000.0,"PreferredStockSharesAuthorized_0_Q1_shares":5500000.0,"UnrecognizedTaxBenefits_0_Q1_USD":0.0,"Ticker":"YMAB","CIK":"1722964","name":"Y-MABS THERAPEUTICS, INC.","OfficialName":"Y-mAbs Therapeutics Inc. Common Stock","form":"10-Q","period":"20200331","fy":"2020.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"556910423.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200507"}]